SIXTH ANNUAL Companion Diagnostics: Strategy, Partnerships, Technology and Adoption
August 18-19, 2015 | Capital Hilton | Washington, DC | Part of CHI’s Seventh Annual Next Generation Dx Summit
Reporter: Aviva Lev-Ari, PhD, RN
SIXTH ANNUAL |
|||||
Strategy, Partnerships, Technology and Adoption August 18-19, 2015 | Capital Hilton | Washington, DC | Part of CHI’s Seventh Annual Next Generation Dx Summit Keynote Session: COMPANION DIAGNOSTICS IN THE CLINIC
NGS offers a powerful tool for assessment of molecular defects found in cancer. The utilization of NGS is becoming common practice in clinical laboratories. This complex technology requires a new level of analytical performance testing and validation. This discussion will focus on approaches used for analytical validation and clinical experience in the MSK-IMPACT program.
Analyses of cancer genomes have revealed mechanisms underlying tumorigenesis and new avenues for therapeutic intervention. In this presentation, I will discuss lessons learned through the characterization of cancer genome landscapes, challenges in translating these analyses to the clinic, and new technologies that have emerged to analyze molecular alterations in the circulation of cancer patients as cell-free tumor DNA. These approaches have important implications for non-invasive detection and monitoring of human cancer, therapeutic stratification, and identification of mechanisms of resistance to targeted therapies. View Full Agenda & Speaker Abstracts | Register | NextGenerationDx.com/Companion-Diagnostics
Only 2 Weeks Away – Secure your Registration Today and Meet 850+ of your Colleagues! For exhibit & sponsorship opportunities, please contact: Joseph Vacca Associate Director, Business Development Cambridge Healthtech Institute T: (+1) 781-972-5431 SOURCE From: Companion Diagnostics <jimp@nextgenerationdx.com> Date: Wednesday, August 5, 2015 at 2:17 PM To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> Subject: Mark Ladanyi and Victor Velculescu / CDx in the Clinic |
Leave a Reply